Juno Therapeutics Backtesting

Juno Therapeutics Inc -- USA Stock  

USD 47.41  1.66  3.63%

With this equity back-testing module your can estimate the performance of a buy and hold strategy of Juno Therapeutics Inc and determine expected loss or profit from investing in Juno Therapeutics over given investment horizon. Please also check Juno Therapeutics Hype Analysis, Juno Therapeutics Correlation, Juno Therapeutics Valuation, Juno Therapeutics Volatility as well as analyze Juno Therapeutics Alpha and Beta and Juno Therapeutics Performance
Investment Horizon     30 Days    Login   to change
SymbolX
Backtest

Juno Therapeutics 'What if' Analysis

November 14, 2017
0.00
No Change 0.00  0.0%
In 30 days
December 14, 2017
0.00
If you would invest  0.00  in Juno Therapeutics on November 14, 2017 and sell it all today you would earn a total of 0.00 from holding Juno Therapeutics Inc or generate 0.0% return on investment in Juno Therapeutics over 30 days. Juno Therapeutics is related to or competes with NantKwest, Del Mar, VBI Vaccines, and Vascular Biogenics. Juno Therapeutics Inc develops cellbased cancer immunotherapies based on its chimeric antigen receptor and T cell recept...

Juno Therapeutics Upside/Downside Indicators

  

Juno Therapeutics Market Premium Indicators

Juno Therapeutics Inc lagged returns against current returns

 Current and Lagged Values 
      Timeline 

Juno Therapeutics regressed lagged prices vs. current prices

 Current vs Lagged Prices 
      Timeline 

Juno Therapeutics Inc Backtested Returns

Macroaxis considers Juno Therapeutics to be not very risky. Juno Therapeutics Inc holds Efficiency (Sharpe) Ratio of -0.0953 which attests that Juno Therapeutics Inc had -0.0953% of return per unit of risk over the last 1 month. Macroaxis philosophy towards determining risk of any stock is to look at both systematic and un-systematic factors of the business, including all available market data and technical indicators. Juno Therapeutics Inc exposes twenty-one different technical indicators which can help you to evaluate volatility that cannot be diversified away. Please be advised to check out Juno Therapeutics Market Risk Adjusted Performance of 0.2892 and Risk Adjusted Performance of (0.05557) to validate risk estimate we provide. Macroaxis gives Juno Therapeutics performance score of 0 on a scale of 0 to 100. The company retains Market Volatility (i.e. Beta) of -2.322 which attests that as returns on market increase, returns on owning Juno Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, Juno Therapeutics is expected to significantly outperform it.. Even though it is essential to pay attention to Juno Therapeutics Inc current price history, it is always good to be careful when utilizing equity current price movements. Macroaxis philosophy towards determining future performance of any stock is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Juno Therapeutics Inc exposes twenty-one different technical indicators which can help you to evaluate its performance. Juno Therapeutics Inc has expected return of -0.4608%. Please be advised to check out Juno Therapeutics Standard Deviation, Maximum Drawdown as well as the relationship between Maximum Drawdown and Expected Short fall to decide if Juno Therapeutics Inc past performance will be repeated at some point in the near future.
Advice Volatility Trend Exposure Correlations
15 days auto-correlation 0.43 

Average predictability

Juno Therapeutics Inc has average predictability. Overlapping area represents the amount of predictability between Juno Therapeutics time series from November 14, 2017 to November 29, 2017 and November 29, 2017 to December 14, 2017. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Juno Therapeutics Inc price movement. The serial correlation of 0.43 indicates that just about 43.0% of current Juno Therapeutics price fluctuation can be explain by its past prices.
Correlation Coefficient 0.43
Spearman Rank Test 0.09
Price Variance 14.5
Lagged Price Variance 6.72

Juno Therapeutics Lagged Returns

 Regressed Prices 
      Timeline 

Juno Therapeutics Performance vs DOW

The median price of Juno Therapeutics for the period between Tue, Nov 14, 2017 and Thu, Dec 14, 2017 is 56.7 with a coefficient of variation of 7.42. The daily time series for the period is distributed with a sample standard deviation of 4.15, arithmetic mean of 55.86, and mean deviation of 3.09. The Stock received some media coverage during the period.
Price Growth (%)  
      Timeline 
1
Analysts Layout Best- And Worst-Case Scenarios Juno Therapeu...12/13/2017